In this study, we uncovered a reciprocal regulatory loop between ERRα and ERG that can promote synergistically the advanced progression of prostate cancer in an AR-independent manner, and suppression of T:E/ETS fusion genes via ERRα targeting could be a potential therapeutic strategy for prostate cancer. The gene discussed is ESRRA; the disease is prostate cancer.